These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21813352)

  • 1. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
    Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
    Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
    Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
    Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma cell leukemia].
    Ravinet A; Bay JO; Tournilhac O
    Bull Cancer; 2014 Nov; 101(11):1048-58. PubMed ID: 25418598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cell leukemia: a rare condition.
    Jiménez-Zepeda VH; Domínguez VJ
    Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary plasma cell leukemia in the era of new drugs: has something changed?
    Musto P; Pagano L; Petrucci MT; Morabito F; Caravita T; Di Raimondo F; Baldini L; Tosi P; Bringhen S; Offidani M; Omede' P; Neri A; D'Auria F; Bochicchio GB; Cavo M; Boccadoro M; Palumbo A
    Crit Rev Oncol Hematol; 2012 May; 82(2):141-9. PubMed ID: 21719304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
    Iriuchishima H; Ozaki S; Konishi J; Matsumoto M; Murayama K; Nakamura F; Yamamoto G; Handa H; Saitoh T; Nagura E; Shimizu K; Nojima Y; Murakami H
    Acta Haematol; 2016; 135(2):113-21. PubMed ID: 26505781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
    Mele G; Pinna S; Melpignano A; Quarta G
    Clin Ther; 2010 May; 32(5):915-9. PubMed ID: 20685499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma cell leukemia: from biology to treatment.
    Jelinek T; Kryukov F; Rihova L; Hajek R
    Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.
    Hovenga S; de Wolf JT; Klip H; Vellenga E
    Bone Marrow Transplant; 1997 Nov; 20(10):901-4. PubMed ID: 9404934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.
    Tessier C; LeBlanc R; Roy J; Trudel S; Côté J; Lalancette M; Boudreault JS; Lemieux-Blanchard É; Kaedbey R; Pavic M
    Cancer Med; 2024 Sep; 13(17):e70192. PubMed ID: 39225552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
    Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.